NFIB post-transcriptionally upregulates the NAD+ salvage synthesis rate-limiting enzyme NAMPT by inhibiting miR-182-5p expression, which could target NAMPT mRNA and inhibit CRC cell proliferation. The gene discussed is NFIB; the disease is colorectal carcinoma.